[Clinical features of tuberculosis among allogeneic hematopoietic stem cell transplantation recipients]

Rinsho Ketsueki. 2021;62(4):239-244. doi: 10.11406/rinketsu.62.239.
[Article in Japanese]

Abstract

The incidence of tuberculosis (TB) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients is 10-40 times higher than that in the general population, which ranges from 0.1% to 5.5%. However, the clinical features of TB among allo-HSCT recipients in Japan remain unknown. We retrospectively analyzed the incidence of TB and the clinical features of culture-positive TB among allo-HSCT recipients at our hospital between 2002 and 2018. Of 1,047 recipients, 5 (0.4%) developed pulmonary TB (with an incidence rate of 472 per 100,000 population) at a median of 1,730 (range: 586-2,526) days after allo-HSCT. Three patients had chronic graft-versus-host disease upon the onset of TB, which was well-controlled with tacrolimus and/or steroid. Three of five patients completed TB treatment, and the disease did not flare up after therapy completion. The incidence of TB was higher in allo-HSCT recipients than in the general population (0.01%, with an incidence rate of 12.3 per 100,000 population). Therefore, TB should be considered a late complication among allo-HSCT recipients.

Keywords: Allogeneic hematopoietic stem cell transplantation; Mycobacterium tuberculosis.

MeSH terms

  • Graft vs Host Disease* / epidemiology
  • Graft vs Host Disease* / etiology
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Japan / epidemiology
  • Retrospective Studies
  • Tuberculosis* / epidemiology